Enteroendocrine L-cell biology — endogenous GLP-1 secretion and regulation

Dr.GutHealth said:

The mechanism is more central than most summaries suggest.

Semaglutide structural biology relevant to the pharmacology: semaglutide is a 31-amino acid peptide with 94% homology to native GLP-1(7-36). Three key modifications enable its pharmacokinetic profile:

1. Aib8 substitution: DPP-4 resistance (prevents enzymatic degradation)
2. Arg34 substitution: improved chemical stability
3. C18 fatty diacid at Lys26: albumin binding → long half-life

These three modifications transform a peptide with a 2-minute half-life (native GLP-1) into one with a 168-hour half-life (semaglutide). A masterclass in peptide engineering.

Dr.GutHealth said:

The mechanism is more central than most summaries suggest.

Pushing back on Dr.GutHealth here. The pharmacokinetics explain nearly every practical question asked here. Albumin binding above 99% slows clearance enough to make weekly dosing possible; a terminal half-life near a week means four to five weeks to steady state and therefore a four-week titration interval; subcutaneous bioavailability around 89% means injection site barely matters. Those three facts answer most timing questions before they are asked.

I would rather be corrected than agreed with, if it comes to it.

Dr.ReproEndo said:

The pharmacokinetics explain nearly every practical question asked here.

Pharmacist here. I want to add the drug interaction perspective on the pharmacology.

Key points from a pharmacokinetic standpoint:

• GLP-1 agonists delay gastric emptying, which can affect Tmax of co-administered oral medications
• Monitor patients on warfarin (INR), levothyroxine (TSH), and oral contraceptives during dose titration
• The albumin-binding mechanism of semaglutide (C-18 fatty acid linker) gives it the ~168-hour half-life that enables weekly dosing
• Steady state is reached at approximately 4-5 weeks after dose initiation or adjustment

Re: the pharmacology specifically — the pharmacology here is well-characterized and the clinical implications are straightforward.

anders_CPH said:

Semaglutide structural biology relevant to the pharmacology: semaglutide is a 31-amino acid peptide with 94% homology to native GLP-1(7-36).

Can confirm. Same sequence, different timescale. The detail I would add is minor and it is already implied above.